Did the first clinical trial of cannabis for PTSD show it works?

No. The first FDA- and DEA-approved RCT of smoked cannabis for PTSD (Bonn-Miller et al., 2021, PLOS ONE), conducted with 76 veterans at the Scottsdale Research Institute, found that all groups — including placebo — showed significant PTSD symptom improvement, with no active cannabis treatment statistically outperforming placebo. Lead researcher Dr. Sue Sisley attributed this partly to the poor quality of NIDA-supplied cannabis.

Can veterans get cannabis through the VA?

The VA remains prohibited from recommending cannabis to veterans as of April 2026. A House-passed amendment in June 2025 would allow VA doctors to recommend cannabis in legal states, but it has not been enacted into law. The VA cannot deny benefits to veterans who use cannabis, but VA physicians cannot recommend or prescribe it.

PTSD in Older Veterans — Cannabis Evidence

Q: Why is PTSD cannabis research so difficult?

PTSD cannabis research faces unique challenges. Cannabis remains Schedule I federally, limiting research access. Until 2021, all cannabis for federally approved research had to come from a single NIDA-contracted facility at the University of Mississippi, which researchers criticized as far below commercial quality. Additionally, strong placebo effects in PTSD trials make it difficult to demonstrate drug-specific benefits.

Vietnam-era veterans aging with PTSD, the Bonn-Miller / Sisley 2021 trial, VA policy realities, and why CannabisVeterans.org is the deeper resource for service-related care.

Particular Urgency, Particular Frustration Limited evidence

PTSD in older veterans presents one of the most urgent areas of cannabis interest — and one of the most frustrating evidence pictures. Many veterans report that cannabis helps manage PTSD symptoms, and veteran advocacy for cannabis access is strong. Yet the only completed RCT failed to show benefit over placebo, and federal policy continues to restrict both research and VA physician recommendations.

The First RCT: All Groups Improved, Including Placebo

The first FDA- and DEA-approved randomized controlled trial of smoked cannabis for PTSD was published by Bonn-Miller et al. (2021, PLOS ONE). The study was conducted at the Scottsdale Research Institute under Dr. Sue Sisley's leadership:

Participants — 76 veterans with PTSD
Design — Randomized, multi-arm trial with different THC/CBD concentrations and a placebo
Result — All groups, including placebo, showed significant PTSD symptom improvement. No active cannabis treatment statistically outperformed placebo.

This result does not prove cannabis cannot help PTSD. It shows that under these specific study conditions, the benefit could not be separated from placebo effects — the improvement seen in all groups may reflect expectations, therapeutic attention, or the structured environment of a clinical trial.

The Cannabis Quality Problem

Dr. Sisley attributed the equivocal results partly to the quality of the cannabis used. Until 2021, all cannabis for federally approved research had to come from a single NIDA-contracted facility at the University of Mississippi. Dr. Sisley described this material as "homogeneous green dust" — far below the potency and quality that patients access at commercial dispensaries.

This is not merely a complaint about aesthetics. If the cannabis used in the trial was substantially weaker or pharmacologically different from what veterans use in practice, the trial may not have tested the same intervention that patients report as helpful. Dr. Sisley subsequently secured a breakthrough DEA Schedule I manufacturing license in 2021, enabling production of research-grade cannabis that more closely matches commercial products — a development that may improve the quality of future trials.

VA Policy: Prohibited from Recommending

The Department of Veterans Affairs occupies an uncomfortable position on cannabis. As of April 2026:

VA physicians cannot recommend or prescribe cannabis — regardless of state law, because cannabis remains a Schedule I controlled substance under federal law
The VA cannot deny benefits to veterans who use cannabis — veterans who test positive for cannabis do not lose their VA healthcare or benefits
A House-passed amendment in June 2025 would allow VA doctors to recommend cannabis in states where it is legal — but this amendment has not been enacted into law as of April 2026

This means that veterans who use cannabis for PTSD are largely on their own medically. Their VA providers cannot guide dosing, recommend products, or monitor for interactions with other VA-prescribed medications — a particularly concerning gap for older veterans taking multiple medications.

Considerations for Older Veterans

Older veterans considering cannabis for PTSD face the same age-related pharmacological realities as all seniors — reduced liver metabolism, increased body fat storage, polypharmacy risks — plus considerations specific to PTSD:

THC and hyperarousal — While some veterans report that THC reduces hypervigilance, THC at higher doses can trigger or worsen anxiety and paranoia, potentially exacerbating PTSD symptoms
REM suppression — THC suppresses REM sleep, which may reduce nightmares in the short term but raises questions about long-term sleep quality and emotional processing
Medication interactions — Many veterans with PTSD take SSRIs, SNRIs, or prazosin. CBD inhibits CYP2D6, which metabolizes several of these medications. See the Antidepressants & Antiepileptics interaction page.

Veteran-Specific Resources

For veterans exploring cannabis for PTSD, the following resources provide additional context:

CannabisVeterans.org — Education and advocacy focused specifically on veterans and cannabis
The Drug Interactions Overview — Essential reading before combining cannabis with any VA-prescribed medications